Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397)

Isabel Syndikus, Rachel C Morgan, Matthew R Sydes, John D Graham, David P Dearnaley, MRC RT01 collaborators, Isabel Syndikus, Rachel C Morgan, Matthew R Sydes, John D Graham, David P Dearnaley, MRC RT01 collaborators

Abstract

Purpose: In men with localized prostate cancer, dose-escalated conformal radiotherapy (CFRT) improves efficacy outcomes at the cost of increased toxicity. We present a detailed analysis to provide further information about the incidence and prevalence of late gastrointestinal side effects.

Methods and materials: The UK Medical Research Council RT01 trial included 843 men with localized prostate cancer, who were treated for 6 months with neoadjuvant radiotherapy and were randomly assigned to either 64-Gy or 74-Gy CFRT. Toxicity was evaluated before CFRT and during long-term follow-up using Radiation Therapy Oncology Group (RTOG) grading, the Late Effects on Normal Tissue: Subjective, Objective, Management (LENT/SOM) scale, and Royal Marsden Hospital assessment scores. Patients regularly completed Functional Assessment of Cancer Therapy--Prostate (FACT-P) and University of California, Los Angeles, Prostate Cancer Index (UCLA-PCI) questionnaires.

Results: In the dose-escalated group, the hazard ratio (HR) for rectal bleeding (LENT/SOM grade >or=2) was 1.55 (95% CI, 1.17-2.04); for diarrhea (LENT/SOM grade >or=2), the HR was 1.79 (95% CI, 1.10-2.94); and for proctitis (RTOG grade >or=2), the HR was 1.64 (95% CI, 1.20-2.25). Compared to baseline scores, the prevalence of moderate and severe toxicities generally increased up to 3 years and than lessened. At 5 years, the cumulative incidence of patient-reported severe bowel problems was 6% vs. 8% (standard vs. escalated, respectively) and severe distress was 4% vs. 5%, respectively.

Conclusions: There is a statistically significant increased risk of various adverse gastrointestinal events with dose-escalated CFRT. This remains at clinically acceptable levels, and overall prevalence ultimately decreases with duration of follow-up.

(c) 2010. Published by Elsevier Inc. All rights reserved.

Figures

Fig. 1
Fig. 1
Prevalence and cumulative incidence of rectal bleeding. (A, B) RMH; (C, D) LENT/SOM. Obj = objective; Std = standard arm, 64 Gy; Esc = escalated arm, 74 Gy; m = month; gr = grade; pre-H = prehormonal therapy; pre-RT = preradiation therapy.
Fig. 2
Fig. 2
Prevalence and cumulative incidence of diarrhea. (A, B) RTOG; (C, D) RMH; (E, F) LENT/SOM; (G, H) UCLA-PCI; (I, J) abdominal pain, UCLA-PCI. Subj = subjective; Std = standard arm; Esc = escalated arm; m = month; gr = grade; pre-H = prehormonal therapy; pre-RT = preradiation therapy.
Fig. 2
Fig. 2
Prevalence and cumulative incidence of diarrhea. (A, B) RTOG; (C, D) RMH; (E, F) LENT/SOM; (G, H) UCLA-PCI; (I, J) abdominal pain, UCLA-PCI. Subj = subjective; Std = standard arm; Esc = escalated arm; m = month; gr = grade; pre-H = prehormonal therapy; pre-RT = preradiation therapy.
Fig. 3
Fig. 3
Prevalence and cumulative incidence of proctitis. (A, B) RTOG; (C, D) rectal urgency, UCLA-PCI. Std = standard arm; Esc = escalated arm; m = month; gr = grade; pre-H = prehormonal therapy; pre-RT = preradiation therapy.
Fig. 4
Fig. 4
Prevalence and cumulative incidence of patient distress and difficulties. (A, B) Bowel distress, UCLA-PCI; (C, D) problems with bowel habits, UCLA-PCI; (E, F) trouble moving bowels, FACT-P. Std = standard arm; Esc = escalated arm; m = month; gr = grade; pre-H = prehormonal therapy; pre-RT = preradiation therapy.

References

    1. Kuban D.A., Tucker S.L., Dong L. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:67–74.
    1. Peeters S.T.H., Heemsbergen W.D., Koper P.C. Dose response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter phase III randomized trial comparing 68 Gy with 78 Gy. J Clin Oncol. 2006;24 1990–1906.
    1. Al-Mamgani A., Van Putten W.L.J., Heemsbergen W.D. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;72:980–988.
    1. Zietman A.L., DeSilvio M.L., Slater J.D. Comparison of conventional-dose versus high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate. JAMA. 2005;294:1233–1239.
    1. Dearnaley D.P., Hall E., Lawrence D. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer. 2005;92:488–498.
    1. Dearnaley D.P., Sydes M.R., Langley R.E. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localized prostate cancer: Results from the MRC RT01 trial (ISRCTN47772397) Radiother Oncol. 2007;83:31–41.
    1. Dearnaley D.P., Sydes M.R., Graham J.D. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007;8:475–487.
    1. Sydes M.R., Stephens R., Moore A. Implementing the UK Medical Research Council (MRC) RT01 trial (ISRCTN 47772397): Methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer. Radiother Oncol. 2004;72:199–211.
    1. Brenner H., Arndt V. Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: Population-based estimates for the year 2000 by period analysis. J Clin Oncol. 2005;23:441–447.
    1. Pilepich M.V., Asbell S.O., Krall J.M. Correlation of radiotherapeutic parameters and treatment related morbidity–analysis of RTOG Study 77-06. Int J Radiat Oncol Biol Phys. 1987;13:1007–1012.
    1. LENT SOMA tables. Radiother Oncol. 1995;35:17–60.
    1. Litwin M.S., Hays R.D., Fink A. The UCLA prostate cancer index: Development, reliability, and validity of a health-related quality of life measure. Med Care. 1998;36:1002–1012.
    1. Esper P., Mo F., Chodak G. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology. 1997;50:920–928.
    1. Koper P.C., Heemsbergen W.D., Hoogeman M.S. Impact of volume and location of the irradiated rectum wall on rectal blood loss after radiotherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 2004;58:1072–1082.
    1. Michalski J.M., Winter K., Purdy J.A. Toxicity after three–dimensional radiotherapy for prostate cancer on RTOG 9406 dose level V. Int J Radiat Oncol Biol Phys. 2005;62:706–713.
    1. Geinitz H., Zimmerman F.B., Thamm R. Late rectal symptoms and quality of life after conformal radiation therapy for prostate cancer. Radiother Oncol. 2006;79:341–347.
    1. Chan L.W., Ping X., Gottschalk A.R. Proposed rectal dose constraints for patients undergoing definite whole pelvic radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;72:69–77.
    1. Heemsbergen W.D., Hoogeman M.S., Hart G.A. Gastrointestinal toxicity and its relation to dose distributions in the anorectal region of prostate cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2005;61:1011–1018.
    1. DeCrevoisieur R., Tucker S., Dong L. Increased risk of biochemical and local failure in patients with distended rectum on the CT planning for prostate radiotherapy. Int J Radiat Oncol Biol Phys. 2005;62:965–973.
    1. Heemsbergen W.D., Hoogeman M.S., Witte M.G. Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: Results from the Dutch trial of 68 Gy versus 78 Gy. Int J Radiat Oncol Biol Phys. 2007;67:1418–1423.
    1. Skala M., Rosewall T., Dawson L. Patient-assessed late toxicity rates and principal component analysis after image-guided radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2007;68:690–698.
    1. Van Der Laan H.P., Van Den Bergh A., Schilstra C. Grading-system-dependent volume effects for late radiation-induced rectal toxicity after curative radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:1138–1145.
    1. Andreyev H.J., Vlavianos P., Blake P., Dearnaley D. Gastrointestinal symptoms after pelvic radiotherapy: Role for the gastroenterologist. Int J Radiat Oncol Biol Phys. 2005;62:1464–1471.
    1. Henderson A., Andreyev H.J.N., Stephens R., Dearnaley D. Patient and physician reporting of symptoms and health-related quality of life in trials of treatment for early prostate cancer: Consideration for future studies. Clin Oncol. 2006;18:735–743.
    1. Hanlon A., Schultheiss T.E., Hunt M.A. Chronic rectal bleeding after high-dose conformal treatment of prostate cancer warrants modification of existing morbidity scales. Int J Radiat Oncol Biol Phys. 1997;38:59–63.
    1. Livsey J.E., Routledge J., Burns M. Scoring of treatment-related late effects in prostate cancer. Radiother Oncol. 2002;65:109–121.
    1. Sanda M.G., Dunn R.L., Michalski J. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250–1261.
    1. Tol-Geerdink J.J., Leer J.W., van Lin E.N. Offering a treatment choice in the irradiation of prostate cancer leads to better informed and more active patients, without harm to well-being. Int J Radiat Oncol Biol Phys. 2008;70:42–48.
    1. McNair H.A., Hansen V.N., Parker C.C. A comparison of the use of bony anatomy and internal markers for offline verification and an evaluation of the potential benefit of online and offline verification protocols for prostate radiotherapy. Int J Radiat Oncol Biol Phys. 2008;71:41–50.
    1. Gulliford S.L., Foo K., Morgan R.C. Dose-volume constraints to reduce rectal side effects from prostate radiotherapy: Evidence from the MRC RT01 trial ISRCTN 47772397. Int J Radiat Oncol Biol Phys. 2009 In press.
    1. Fonteyne V., Villeirs G., Speleers B. Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion. Int J Radiat Oncol Biol Phys. 2008;72:799–807.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit